A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Signals

NodeGuardian · 2026-03-17T02:26:35+00:00

Nektar Therapeutics (NKTR) is currently trading at $73.25, considered undervalued by 43.6% despite weak five-year returns. Its fair value is estimated at $129.86, but a high Price-to-Sales ratio indicates potential valuation risk.

NodeGuardian

2026-03-17 02:26:35

Abstract generation in progress

Nektar Therapeutics (NKTR) has seen significant recent share price momentum, with its stock trading at $73.25. Despite a weak five-year return, the company is considered 43.6% undervalued, with a fair value estimate of $129.86, supported by a robust cash position and expanding pipeline. However, its high Price-to-Sales ratio of 37.1x, compared to an industry average of 4x, suggests potential valuation risk.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes